Reuters logo
BRIEF-Novimmune ‍receives rare pediatric disease designation from FDA for its lead drug emapalumab​
September 5, 2017 / 5:06 AM / 3 months ago

BRIEF-Novimmune ‍receives rare pediatric disease designation from FDA for its lead drug emapalumab​

Sept 5 (Reuters) - Novimmune SA (IPO-NOVI.S):

* ‍RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM FDA FOR ITS LEAD DRUG EMAPALUMAB​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below